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Abstract:  
Objective: In line with the recent global action plan for antimicrobial resistance, the first time such a comprehensive 
survey has been undertaken in Pakistan, sixth most populous country.  
Method: This point prevalence survey (PPS) was conducted in 13 hospitals among 7 different cities of Pakistan. The 
survey included all inpatients receiving an antibiotic on the day of PPS. A web-based application was used for data 
entry, validation, and reporting as designed by the University of Antwerp.  
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Results: Out of 1954 patients, 1516 (77.6%) were treated with antibiotics. Top three most reported indications for 
antibiotic use were prophylaxis for obstetrics or gynaecological indications (16.5%) and gastrointestinal indications 
(12.6%) and lower respiratory tract infections (12.0%). Top three most commonly prescribed antibiotics were 
ceftriaxone (35.0%), metronidazole (16.0%) and ciprofloxacin (6.0%). Out of total indications, 34.2% of antibiotics 
were prescribed for community-acquired infections (CAI), 5.9% for healthcare-associated infections (HAI), and 
57.4% for either surgical or medical prophylaxis. Of total surgical prophylaxis, 97.4% of antibiotics were given for 
more than one day.  
Conclusion: Study concluded that unnecessary prophylactic antibiotic use is extremely high and broad-spectrum 
prescribing is common. There is a considerable need to work on a national action plan of Pakistan on antibiotic 
resistance.  
Keywords: Point Prevalence Survey, Antimicrobial Prescribing, Antimicrobial Resistance, Hospitals, Pakistan  
1. INTRODUCTION 
Infectious diseases were the major cause of death in humans until 1911 when the first antibiotic agent was 
introduced as a “magic bullet” [1,2]. Since their development, the significant role of antibiotics in saving lives has 
been evident [3]. However, all these benefits are related to their rational use [4]. Unfortunately, the irrational use of 
antibiotics increases the risk of development of antimicrobial resistance (AMR), increasing morbidity, mortality and 
costs, with costs including additional visits to emergency departments, extra prescriptions for adjuvant therapies as 
well as prolonged hospital stay, leading to worldwide calls to address this [5-13]. For example, colistin has re-emerged 
as a valued antibiotic despite its side-effects because of the emergence of carbapenem-resistant gram-negative bacteria 
[14,15]. This has resulted in a number of countries, including South Africa, to develop programmes to limit its use to 
preserve its effectiveness [16], with colistin also now included in the WHO reserve list of antibiotics [17]. According 
to the Council for Appropriate and Rational Antibiotic Therapy (CARAT), criteria for optimized antibiotic therapy 
include therapeutic safety and benefits, evidence-based results, cost-effectiveness and the optimal antibiotic for the 
optimal duration [18].  Appropriate dosing regimens should be adopted by following guidelines for antibiotic 
prescribing [18,19].  
Data on antibiotic use in healthcare settings in Pakistan are currently scarce. We are aware of the excessive 
use of antibiotics in ambulatory care [20-22]. However, only a few published studies are available regarding the pattern 
of antibiotic use in Pakistan in hospitals [23,24] including their irrational use [25]. We are also aware that there have 
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been initiatives to try and improve antibiotic use using antibiotic stewardship programmes (ASP) in Pakistan [26]. 
Contrary to other countries and continents including Africa, Americas, Asia, Australia, Europe, Kenya, and Turkey 
[27-36], no point prevalence survey (PPS) to evaluate antimicrobial use and resistance has so far been conducted in 
Pakistan. This is important to address concerns with the irrational use of antimicrobials in hospitals in Pakistan. 
Consequently, the main objectives of this multicenter PPS were to evaluate the prevalence of antibiotic use among 
hospitals in Pakistan and to describe the current pattern of antibiotic prescribing by type of patient’s characteristics, 
healthcare facilities, and specialties. This builds on our recently published study regarding the prevalence of hospital-
acquired infections in Pakistan [37]. The findings will help inform future strategies to improve antibiotic prescribing 
among hospitals in Pakistan. 
2. METHODOLOGY: 
2.1. Study Design:  
A multicenter PPS of antibiotic use was conducted using the Global-PPS method [36,38]. This standardized survey 
method was used to document and evaluate antimicrobial prescribing patterns at hospital, ward and patient level. 
2.2.  Study Settings: 
The study setting for this first PPS study in Pakistan was Punjab. Punjab was chosen as the study region because it is 
the most populous province of Pakistan. A complete list of all public, private and charity hospitals of Punjab were 
acquired from the Director General Health Services office, Department of Health, Government of the Punjab, Pakistan. 
The hospitals from public, private and charity hospital groups from the different cities in Punjab, Pakistan were invited 
to participate in this survey. In case of refusal of the first selected hospital, the next health care setting on the list was 
selected. Participation of the hospital was voluntary. Thirteen hospitals from geographically and economically 
different cities of Punjab agreed to participate in the survey, which provided a representative insight into current 
antimicrobial prescribing practices. The health care facilities providing only nursing care, rehabilitation centers or 
psychiatric centers were not included in line with other PPS studies [36,39]. 
2.3. Instrument of Measure: 
Standardized paper data collection forms were used to collect data at each hospital, ward and patient level. The hospital 
data form included the type of the hospital, departments, number of hospitalized patients, single-room bed capacity 
and total bed capacities of the surveyed hospital. A review of the availability of antibiotics in the hospital formulary 
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was checked before data collection. The Ward data form included the department specialty, total bed capacity and the 
total number of admitted patients (denominator data). The Patient data form included the age, gender, reason for 
antibiotic prescribing, the prescribed antibiotics dosage regimen, the antibiotic prescription ratio active, and the 
causative microorganisms. For the dose of a combination antimicrobial, the sum of each antibiotic substance excluding 
the enzyme inhibitors was recorded. A set of quality indicators included whether the reason for the prescription and a 
stop/review date was written in the notes; and whether the antibiotic was prescribed according to the guidelines if this 
existing, with the latter increasingly indicative of quality prescribing [36,40,41]. A web-based application was used 
for data-entry, validation, and reporting as designed by the University of Antwerp [36,38]. 
 
2.4. Inclusion criteria: 
All in-patients that stayed overnight and remained in the ward at 08:00 am on the day of the survey were included. 
Data were collected only from those patients who were receiving at least one antimicrobial for at least one clinical 
treatment condition or prophylaxis at the time of the survey. Beside antibacterials for systemic use, the survey included 
also antimycotics, antifungals and antivirals for systemic use infections in more than one site in the same patient were 
reported as separate infections. 
2.5. Exclusion criteria 
Short stay patients that did not stay overnight, those discharged patients before 08.00 am on the day of the survey that 
were waiting for transport to their dwelling, patients admitted after 8am on the day of the survey, patients staying in 
long-term care units including dialysis centers and patients in emergency and outpatient departments were not 
included.  
2.6. Data Collection: 
The data were collected using a structured data collection tool [36,38]. All patients admitted on the ward at 08.00 am 
on the day of the survey were counted in the denominator. Whereas, all inpatients on antimicrobials at 08.00 am were 
included in the numerator, and forms were completed for these patients only. All the prescribed antimicrobials at the 
time of the survey were included. Patients were included as part of the initial ward of admittance if transferred to 
another ward after 8.00 a.m. All neonates born before 08.00 am on the day of the survey were also included. The 
surgical wards were not surveyed on a day following a holiday but on the other days of the week in order to capture 
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information about prophylaxis in the last 24 hours [36]. Surgical prophylaxis included prophylactic agents to prevent 
surgical site infections. Long-acting antibiotics and intermittent treatment on alternative days were also included if 
given 24 hours before the survey. Medical prophylaxis was defined as the use of antibiotics to prevent infections in 
patients with medical conditions [36]. Infections were considered as community-acquired infections (CAIs) if 
symptoms started <48 hours from admission to hospital (or present on admission), and hospital-acquired infections 
(HAIs) if symptoms started 48 hours after admission [36]. The last prescribed antibiotic was recorded if the antibiotic 
prophylaxis or treatment was changed on the day of the survey before or at 08.00am. Additional details of the variables 
from the patient’s medical case notes and prescribing charts were recorded after discussions with nursing staff and 
physicians if pertinent. However, in most cases, only the patients’ notes were reviewed in order to gain a good 
understanding of the current situation especially if crucial data was left out such as the rationale for antibiotic selection. 
The data were double checked for completeness and accuracy in order to rule out missing or inconsistent data. There 
was no contact with any patient at any moment. All the data were entered onto the web-based Global-PPS application 
[38]. Data from all wards of a single hospital were collected within 2-4 weeks. In order to minimize the effect of 
movement of patients between wards and within the hospital, each ward was completely surveyed within one day. 
The process of data collection was completed between October 2017 and February 2018. The Anatomical Therapeutic 
Chemical (ATC) classification system of the WHO was used to classify the different antibiotics used [42].  
2.7. Ethical Considerations: 
Application for Ethical clearance prior to the conduct of the study was sought from the Human Ethics Division of 
University College of Pharmacy, University of the Punjab, Lahore (HEC/1000/PUCP/1925B). Subsequent approval 
to conduct the study in the identified hospitals was obtained from the hospital management. All collected data were 
anonymized during the time of data collection.  
2.8. Statistical Analysis 
Data were analyzed using the latest versions of Microsoft Excel and SPSS (version 22 IBM, California, USA). On 
categorical variables, descriptive statistics (frequency, percentages, mode, and medians) were applied. Continuous 
variables were presented with median and range.  
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3. RESULTS:  
A total of 13 hospitals with 3074 beds were surveyed in this prevalence study from seven different cities of Pakistan. 
The survey was conducted in five private and eight public sector hospitals including secondary, tertiary and specialized 
health care facilities. Basic patient data from the different hospitals treated with antimicrobials is presented in Table 
1. During this PPS, 1954 (63.6% bed occupancy) patients with a median age of 35 years were hospitalized on the day 
of the survey.  Out of these, 1516 patients (77.6%) were treated with one or more antimicrobials of which 1503 patients 
received at least one antibiotic for systemic use (76.9%; ATC code J01). There was an appreciable variation in 
antibiotic use prevalence across the hospitals, ranging from 50.9%-100% of all patients in the hospital.  
The total number of prescribed antimicrobials was 2483 (J01; 96.6%, J02; 0.4%, J04; 0.8%, J05; 0.8%, P01; 0.6%, 
A07; 0.7%) (Table 2), of whom 1177 (47.7%) were given to male patients and 1306 (52.6%) were given to female 
patients. The average number of antimicrobials prescribed per patient (1.64) ranged from 1.14 to 1.97 antimicrobials 
per patient. Nine hundred and sixty-one (38.7%), 1,404 (56.5%) and 118 (4.8%) antibiotics were prescribed in surgical 
departments, medical departments, and ICU, respectively (Table 1). Parenteral (91.5%) antibiotic use was very 
prevalent. Of the total prescribed antibiotics, 55.5% were prescribed to patients in the age group 25-65 years, followed 
by 26.3%, 8.9%, 6.5% and 2.7% to patients in the age groups 1-25 years, above 65 years, 1 month-1 year and less 
than 1 year respectively (Appendix 1). The admitted patients were more likely to receive antibiotics as prophylaxis 
(57.4%).  Of the total 1,426 antibiotics for prophylactic use, 893 (62.6%) were used for surgical prophylaxis whereas 
533 (37.4%) were prescribed for medical prophylaxis. Most of the antibiotics for surgical prophylaxis were given for 
more than one day (97.4%).  For the management of infections, 850 (85.3%) antibiotics were given for CAIs whereas 
147 (14.7%) were given for HAIs.   
In the majority of cases, the reasons for prescribing the various antibiotics were not mentioned in the patient’s 
medical file (76.2%).  Only 57 culture reports were found at the time of the survey as most of the antibiotics were 
prescribed empirically (96.2%).  Fifty-eight different types of antibiotics were used, but just two (ceftriaxone and 
metronidazole) comprised 51% of all antibiotic treatment. Most of the hospitals were using 20 different types of 
antibiotic substances, ranging from 9-30. Of the total number of antibiotics prescribed, 772 (50.9%) patients were 
prescribed one antibiotic, 558 (36.8%) were prescribed two antibiotics and 186 (12.3%) patients were prescribed three 
or more antibiotics.  
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 Most of the surveyed patients were admitted into the general medical wards (25.0%), surgical wards (18.4%) 
and obstetrics and gynecology wards (14.4%). Other than these wards, all other wards were also surveyed as per the 
hospital specialty. The details about the use of the different antimicrobials in the different clinical wards and medical 
indications are summarized in Tables 3 and 4. Appendixes 2 to 4 provide details at the hospital level.  Obstetric or 
gynecological prophylaxis (16.5%), gastrointestinal prophylaxis (12.6%), lower respiratory infections (12.0%) and 
general medical prophylaxis (10.5%) were the most common clinical indications for antibiotic use.  
The top three most commonly prescribed antibiotics were ceftriaxone (35.0%), metronidazole (16.0%) and 
ciprofloxacin (6.0%) (Table 3). Ceftriaxone remained the most used antibiotic for different treatments or prophylactic 
use, ranging from on average 12.7% of use in the ICU to on average 40.4% of use in the medical departments (Table 
4). In addition to these top three commonly used antibiotics, there was a relatively high use of amikacin (11.0%), 
meropenem (10.2%), piperacillin and enzyme inhibitor (10.2%) and vancomycin (9.3%) was observed among ICU 
patients compared to other departments.  Metronidazole IV was highest for surgical prophylaxis (26.7%). Ampicillin 
was most frequently used in neonates (8.8%) and infants (20.8%). Moxifloxacin was frequently prescribed among 
patients aged 25-65 years (4.4%) and age above 65 years (9.0%). It proved impossible to assess the quality of 
prescribing as currently there are no accepted national guidelines giving advice on antimicrobial prescribing  [43].  
4. DISCUSSION: 
Effective surveillance of antibiotic use is invaluable to help rationalize antibiotic prescribing, thereby helping control 
the emergence of multidrug resistance microbes, observing the efficiency of policies, identifying targets for quality 
improvement and informing the policymakers [7,9,28,44,45]. The global threat of increasing AMR prompted us to 
conduct this first point prevalence survey among selected hospitals of Pakistan [10]. In the present study, 77.6% of 
admitted patients on one single day had consumed at least one antimicrobial. This is much higher than prevalence 
rates reported in other PPS studies across the world including the Global PPS (34.4%), Europe (27.4% - 34.4%%), 
Asia including China  (37.2% - 55.6%), North America (38.6% - 50.0%)  and Turkey (30.6%) [28,32-34,36,44].  
However, this is similar to some of the hospitals seen in the Global PPS study, particularly the African countries,  as 
well as Botswana and Kenya [36,46,47] but not Ghana (51.4%) [48]. In Botswana, more than two-thirds of admissions 
in their PPS study were due to infectious diseases with 40% of those tested were HIV positive [47]. In addition, our 
results are comparable with other hospitals in China (75.3%) [49], which has already resulted in the instigation of 
antibiotic stewardship strategies in China to address antibiotic overuse [50-52]. Among the identified regions 
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worldwide, the highest use of antibiotics was seen in intensive care units (ICU) of Vietnam (84.6%) among the adult 
population [53]. In the Global PPS, up to 69.7% of patients in ICU were prescribed an antibiotic [36], similar to the 
findings in Kenya [46]. We also saw a high use of antibiotics in ICU.  
There was also a high use of antibiotics for medical prophylaxis in our study (37.4% of 57.4% of patients who received 
an antimicrobial). This is similar though to the situation seen in Kenya (29% of antimicrobial use) but much lower 
than seen in the Global PPS (7.4%) [36,46]. The reasons for this high rate are currently unknown; however, this will 
be investigated further to reduce inappropriate antimicrobial prescribing. Approximately  50% of patients were 
prescribed two or more antibiotics in our study, which is similar to a study conducted in America [33]. We believe 
this high rate of combination antibiotic treatment is needed to increase the spectrum of antibiotics prescribed without 
the support of a culture report. This is also a concern that needs to be addressed, and we will be pursuing this in future 
projects. In the present study, the most commonly prescribed antibiotic was ceftriaxone (35%) which is comparable 
to a study from China [49], with ceftriaxone included in the WHO list of Access antibiotics [17]. In other regions, 
however, such as in 183 hospitals of the USA, the prevalence of ceftriaxone use was only 10.8% [33].  The majority 
of antibiotics prescribed were also on the WHO list of Access antibiotics (Table 3), with moxifloxacin, piperacillin 
with an enzyme inhibitor and cefoperazone on the Watch list [17]. Their use will be the subject of future research 
projects. 
In the present study, ceftriaxone was also commonly prescribed for surgical prophylaxis, similar to a number 
of regions in the Global PPS particularly Africa as well as in Kenya for surgical prophylaxis [36,46]. The routinely 
use of ceftriaxone for prophylaxis in our study is of concern as it should not routinely be used for prophylaxis [54]. 
Inappropriate ceftriaxone use can lead to the emergence of multidrug-resistant strains if not addressed [55,56]. There 
is also concern that antibiotics for surgical prophylaxis were given for more than one day (97.4%), which is against 
current guidance as this can increase AMR rates [57,58]; however, this is similar to the situation seen in other countries 
[36,46,59].  The threat of surgical site infections should not be ignored while following guidelines [60,61]. A number 
of studies have highlighted that even in the most documented evidence-based area of practice, physicians are inclined 
to prescribe antibiotics for more than 24 hours [62]. As a result, physicians should be encouraged to write the reason 
to start antibiotic treatment, document the start date and follow up the duration of use in the patient’s medical notes. 
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This will be followed up in future studies. The high use of ceftriaxone in this study also suggests cheap, easy or free 
availability and affordability, which needs to be researched further [63].  
As mentioned,  there are almost no local or national guidelines or recommendations for empiric antibiotic use in 
hospitals in Pakistan [43]. Our results suggest the urgent need to develop these starting with guidelines for the most 
common indications as well as for surgical and medical prophylaxis. This could be part of an ASPs to be developed 
at a national level, and could also be part of the national action plan of Pakistan for AMR [64]. The UK, for example, 
has successfully managed to reduce the use of the third-generation cephalosporins by introducing antimicrobial 
stewardship programs [65,66], providing guidance to others. In addition, a lower proportion of broad-spectrum 
antibiotics indicates better practice [67]. It is also important that ASP also include quality targets, a timeline as well 
as a dedicated budget to achieve desired goals. However, it is acknowledged that it is more challenging introducing 
ASPs in LMICs due to a number of issues including manpower challenges [68]. 
Variations in antibiotic use patterns may also be due to differences in the spectrum of diseases and the facilities across 
countries and regions; however, this needs to be investigated further before any definitive statements can be made. 
There is also likely to be variation among the departments in the pattern of antibiotic use within hospitals in Pakistan. 
For example, large and specialized hospitals have more immunocompromised or severely injured and ill patients, or 
those in need of complex surgical procedure, as compared to small hospitals affecting utilization patterns [31]. 
Encouragingly, the use of quinolones in the present study is comparable to most of the European countries but less 
than those reported in France [31,69,70]. Overall, the extensive use of broad-spectrum antibiotics in Pakistan could 
be explained by high bacterial resistance rates [71], and the potential for practitioners to overprescribe antibiotics if 
they view such practices as a viable way to ensure a speedy recovery [72,73]. Additionally, physicians in Pakistan 
may be influenced by pharmaceutical companies if they are the principal source of information as seen in other settings 
in Pakistan and other countries [21,74-76].  
Another concern is the very high usage (91.5%) of parenteral antibiotics observed in this study as compared 
to previously published PPS studies [45]. We believe this goes hand in hand with the high use of third-generation 
cephalosporins (ceftriaxone) for which no oral equivalent is currently available. Nevertheless, many physicians and 
patients consider that parenteral therapy is superior and more effective than oral administration [77]. Moreover, the 
use of parenteral antibiotics is inevitable in case of life-threatening infections, the age of the patient especially infants, 
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and the availability of dosage form. Whenever possible though, each hospital should develop individual guidelines to 
switch from intravenous to oral treatment in view of the several clinical and economic benefits associated with timely 
conversion to oral from intravenous therapy [78,79].  In our study, physicians of only one specialized cancer care 
hospital were found to prescribe fewer antibiotics (50.9%) as per the advice of pharmacists. The literature supports 
the fact that interventions of a pharmacist by interacting directly in the ward with physicians can play an important 
role in optimizing antibiotic prescribing, leading to a decrease in health care costs and days of hospitalization [80,81]. 
This will also be followed up in future studies. 
Finally, as seen, prophylactic antibiotic use without culture reports was high, relatively much higher in 
smaller hospitals of those surveyed. This reflects the general lack of reporting the rationale for antimicrobial use. As 
a result, as mentioned, physicians should be encouraged to write the reason to start antibiotic treatment in the patient’s 
medical notes. The present study has a number of limitations. Firstly, it was impossible to assess the appropriateness 
of antibiotic therapy in terms of choice and duration. Nonetheless, surveillance is the first step in identifying, 
appraising and progressing the existing situation with respect to inappropriate antibiotic prescribing. Secondly, a 
number of patient’s medical notes were not sufficient to evaluate the diagnosis of infection. This may have 
underestimated or overestimated infection rates. Thirdly, as this was the first PPS in these hospitals, sequential surveys 
should be conducted to reveal any seasonal changing epidemiology among the hospitals [82]. Lastly, because 
participation of hospital was solely voluntary, data cannot be generalized to the whole of Pakistan because only a few 
hospitals of one Province participated in the survey. In spite of the above-mentioned limitations, the present survey 
provides insight into the prevalence and pattern of antibiotic use in Pakistan. The outcomes of this survey highlight 
the significance of surveillance of antibiotics and the need of antibiotic policies to enhance the appropriate use of 
antibiotics in the future. The findings of this survey could be the basis for planning future goals for appropriate 
management of antibiotic use and antibiotic stewardship including developing pertinent quality indicators based on 
previous studies [36,40]. The important features of this methodology are its ease of use and cost-effectiveness. 
5. CONCLUSION AND RECOMMENDATIONS: 
There is considerable cause for concern regarding the current use of antibiotics in hospitals in Pakistan. Consequently, 
there is an urgent need to start working on a national action plan in Pakistan in order to rationalise the use of antibiotics. 
Stewardship efforts, in particular, should be focused on the use of ceftriaxone especially any prophylactic use, the 
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length of prophylaxis and the reasons for antibiotic prescribing in the first place. In addition, the rapid conversion to 
oral antibiotics should be implemented where pertinent. To preserve the future effectiveness of antibiotics and reduce 
patient harm due to AMR, it is imperative to rationally scrutinize and improve the prescribing practices.  The study is 
a first step to provides an insight into antibiotic use among Pakistani hospitals and highlights directions for 
improvement of antibiotic prescribing quality. Taken together, a multifaceted policy that includes regulation, 
collaboration, education, and increased financial support is required at the national level in Pakistan. Future studies 
can also be part of the Global PPS study to enhance comparisons with other LMICs. 
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Table 1: Overall antibiotic use prevalence  
 
Characteristics N (%) Hosp. A i Hosp. B  Hosp. C Hosp. D Hosp. E ii Hosp. F iii Hosp. G ii Hosp. H Hosp. I Hosp. J Hosp. K Hosp. L Hosp. M Total 
 
Hospital Type Public Charity Public Private Charity Charity Public Public Public Private Public Public Public  
Total beds 451 233 86 67 190 195 361 166 107 239 282 355 342 3074 
Hospitalized patients 373 (82.7) 102 (43.7) 72 (83.7) 36 (53.7) 93 (48.9) 161 (82.6) 212 (58.7) 96 (57.8) 75 (70.1) 106 (44.4) 112 (39.7) 286 (80.6) 230 (67.3) 1954 (63.6) 
Number of treated patients 281 (75.3) 97 (95.0) 68 (94.4) 27 (75.0) 65 (69.8) 82 (50.9) 148 (69.8) 79 (82.3) 75 (100) 89 (84.0) 74 (66.1) 230 (80.4) 201 (87.4) 1516 (77.6) 
Prescribed antibiotics (per 
patient) 
481 149 122 51 108 140 291 105 127 134 84 338 353  2483 
Surgical Department N (%) 267 (55.5) 48 (32.2) 73 (59.8) 38 (74.5) 61 (56.5) 19 (13.6) 73 (25.1) 5 (4.8) 73 (57.5) 23 (17.2) 48 (57.1) 182 (53.8) 85 (24.1) 961 (38.7) 
Medical Department N (%) 208 (43.2) 98 (65.8) 49 (40.2) 4 (7.8) 40 (37.0) 105 (75.0) 199 (68.4) 97 (92.4) 54 (42.5) 72 (53.7) 23 (27.4) 156 (46.2) 265 (75.1) 1404 (56.5) 
Intensive Care Unit N (%) 6 (1.2) 3 (2.0) 0 9 (17.6) 7 (6.5) 16 (11.4) 19 (6.5) 3 (2.9) 0 39 (29.1) 13 (15.5) 0 3 (0.8) 118 (4.8) 
Male 172 (35.8) 63 (42.3) 57 (46.7) 33 (64.7) 53 (49.1) 84 (60.0) 104 (35.7) 62 (59.0) 62 (48.8) 67 (50.0) 33 (39.3) 178 (52.7) 209 (59.2) 1177 (47.4) 
Female 309 (64.2) 86 (57.7) 65 (53.3) 18 (35.3) 55 (50.9) 56 (40.0) 187 (64.3) 43 (41.0) 65 (51.2) 67 (50.0) 51 (60.7) 160 (47.3) 144 (40.8) 1306 (52.6) 
Route of administration               
Oral 31 (6.4) 18 (12.1) 0 2 (3.9) 15 (13.9) 25 (17.9) 15 (5.2) 2 (1.9) 9 (7.1) 25 (18.7) 24 (28.6) 30 (8.9) 13 (3.7) 209 (8.4) 
Parenteral 450 (93.6) 131 (87.9) 122 (100) 49 (96.1) 93 (86.1) 115 (82.1) 276 (94.8) 103 (98.1) 118 (92.9) 109 (81.3) 60 (71.4) 308 (91.1) 340 (96.3) 2274 (91.5) 
Indication               
Therapeutic use 124 (25.8) 57 (38.3) 37 (30.3) 16 (31.3) 42 (38.9) 106 (75.7) 112 (38.5) 26 (24.8) 59 (46.5) 75 (56.0) 36 (42.9) 111 (32.8) 151 (42.8) 997 (40.2) 
Prophylaxic use 351 (73.0) 83 (55.7) 84 (68.9) 31 (60.6) 66 (61.1) 34 (25.3) 154 (52.9) 76 (72.4) 68 (53.5) 54 (40.3) 48 (57.1) 226 (66.9) 197 (55.8) 1426 (57.4) 
Unknown 6 (1.2) 9 (6.0) 1 (0.8) 4 (7.8) 0 0 25 (8.6) 3 (2.9) 0 5 (3.7) 0 1 (0.3) 5 (1.4) 59 (2.4) 
Indication for prophylaxis               
Medical 110 (31.3) 33 (39.7) 25 (29.7) 8 (25.8) 18 (27.3) 18 (52.9) 34 (77.9) 54 (71.1) 26 (38.2) 30 (55.5) 18 (37.5) 78 (34.5)  81 (53.6) 533 (37.4) 
Surgical 241 (68.6) 50 (61.3) 59 (70.3) 23 (74.2) 48 (73.7) 16 (47.1) 120 (22.1) 22 (28.9) 42 (61.8) 24 (44.5) 30 (62.5) 148 (65.5) 70 (46.3) 893 (62.6) 
Surgical prophylaxis               
Single dose 0 3 (6.0) 0 0 0 0 0 0 2 (4.8) 1 (4.2) 0 4 (2.7) 0 10 (1.1) 
One day 5 (2.1) 0 3 (5.1) 0 1 (2.1) 0 1 (0.8) 0 0 0 0 3 (2.0) 0 13 (1.5) 
More than one day 236 (97.9) 47 (94.0) 56 (94.9) 23 (100) 47 (97.9) 16 (100) 119 (99.2) 22 (100) 40 (95.2) 23 (95.8) 30 (100) 141 (95.3) 70 870 (97.4) 
Indication for infection               
Community-acquired 116 (93.5) 53 (93.0) 31 (83.7) 9 (56.3) 32 (76.2) 69 (65.1) 105 (93.7) 22 (84.6) 55 (93.2) 45 (60.8) 27 (75.0) 99 (89.2)  187 (94.9) 850 (85.3) 
Hospital-acquired 8 (6.5) 4 (7.0) 6 (16.3) 7 (43.7) 10 (24.8) 37 (34.9) 7 (6.3) 4 (15.4) 4 (6.8) 29 (39.2) 9 (25.0) 12 (10.8) 10 (5.1) 147 (14.7) 
Reason on Notes               
Yes 88 (18.3) 25 (16.8) 11 (9.0) 4 (7.8) 3 (2.8) 78 (55.7) 25 (8.6) 15 (14.3) 44 (34.6) 47 (35.1) 16 (19.0) 87 (25.7) 147 (41.6) 590 (23.8) 
No 393 (81.7) 124 (83.2) 111 (91.0) 47 (92.2) 105 (97.2) 62 (44.3) 266 (91.4) 90 (85.7) 83 (65.4) 87 (64.9) 68 (81.0) 251 (74.3) 206 (58.4) 1893 (76.2) 
Empirical Therapy 480 (99.8) 148 (99.3) 122 (100) 48 (94.1) 104 (96.3) 92 (65.7) 285 (97.9) 104 (99.0) 127 107 (79.9) 84 (100.0) 335 (99.1) 353 (100.0) 2389 (96.2) 
Types of Generics used 22 15 9 14 23 26 29 15 13 30 11 22 23 19 
Culture Reports 1 1 0 3 4 22 1 0 0 25 0 0 0 57 
 
i Public Sector Teaching Hospital, ii Specialized Spine and Orthopedic Hospital, iii Specialized Cancer Care Hospital with advance Clinical Pharmacy Services 
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Table 2: Use prevalence of main antibiotics classes  
 
Antibiotics  N (%) Hospital range 
% 
 
ANTIBACTERIALS FOR SYSTEMIC USE (J01) 2398 (96.6) 85.0-100.0 
Tetracyclines (J01A)  23 (0.8) 0.0-5.9 
Penicillins (J01C) 293 (11.8) 0.0-35.0 
Cephalosporins & Penams  (J01D) 1218 (49.1) 0.0-70.2 
Sulfonamides & trimethoprim (J01E) 5 (0.2) 0.0-2.9 
Macrolides & lincosamides (J01F) 51 (2.1) 0.0-5.2 
Aminoglycosides (J01G) 88 (3.5) 0.0-11.9 
Quinolones (J01M) 282 (11.4) 0.0-24.6 
Other antibacterials (J01X) 458 (18.4) 0.0-31.1 
ANTIMYCOTICS FOR SYSTEMIC USE(J02) 11 (0.4) 0.0-7.1 
ANTIMYCOBACTERIALS FOR SYSTEMIC USE (J04)  21 (0.8) 0.0-6.5 
ANTIVIRALS FOR SYSTEMIC USE (J05) 21 (0.8) 0.0-3.6 
ANTIPROTOZOALS (P01) 15 (0.6) 0.0-3.6 
ANTIDIARRHEALS (A07) 17 (0.7) 0.0-4.5 
 
 
Table 3: Top 10 indications and antibiotics  
 
 Top 10 Indications Top 10 Antibiotics 
No.   
 Indications N (%) Antibiotics  N (%) 
   
1. P. OBGY 408 (16.5) Ceftriaxone  868 (35.0) 
2. P. GI 313 (12.6) Metronidazole 397 (16.0) 
3. LRTI 297 (12.0) Ciprofloxacin 150 (6.0) 
4. General MP 260 (10.5) Co-amoxiclav 91 (3.7) 
5. SST 170 (6.8) Moxifloxacin  86 (3.5) 
6. P. BJ 149 (6.0) Piperacillin, enzyme inhibitor 82 (3.3) 
7. SEPSIS 145 (5.9) Cefoperazone 73 (2.9) 
8. GIT 118 (4.8) Amikacin 69 (2.8) 
9. P. RESP 95 (3.8) Ampicillin 68 (2.7) 
10. CNS 62 (2.5) Vancomycin 59 (2.4) 
 
BJ; Bone & Joint, CNS; Central Nervous System, GIT; Gastro-Intestinal Tract, MP; Medical Prophylaxis, OBGY; Obstetric or 
Gynaecological, LRTI; Lower Respiratory Tract Infection, P; Medical or Surgical Prophylaxis, RESP; Respiratory, SST; Skin and Soft 
Tissues 
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Table 4: Top 5 antibiotics in different conditions   
 
Study Variables  Ranks  
1 2 3 4 5 
 
DEPARTMENT      
ICU Ceftriaxone  
15 (12.7)  
Amikacin  
13 (11.0) 
Meropanam  
12 (10.2) 
Piperacillin & 
enzyme inhibitor  
12 (10.2) 
Vancomycin  
11 (9.3) 
Medical Ceftriaxone  
567 (40.4) 
Ciprofloxacin  
58 (4.1) 
Piperacillin & 
enzyme inhibitor  
58 (4.1) 
Moxifloxacin  
57 (4.1) 
Ampicillin  
52 (3.7) 
Surgical Ceftriaxone  
286 (29.8) 
Metronidazole  
218 (22.7)  
Cefoperazone  
66 (6.9) 
Co-amoxiclav  
47 (4.9) 
Cefotaxime  
42 (4.4) 
 
AGE GROUPS       
<1month Ceftriaxone 
16 (23.5) 
Amikacin  
11 (16.2) 
Cefotaxime 
11 (16.2) 
Ampicillin 
6 (8.8) 
Ciprofloxacin 
4 (5.9) 
1 month-1year Ceftriaxone 
70 (44.0) 
Ampicillin 
33 (20.8) 
Metronidazole 
10 (6.3) 
Amikacin  
7 (4.4) 
Ceftazidime 
6 (3.8) 
1 year-25years Ceftriaxone 
228 (34.6) 
Metronidazole 
127 (19.3) 
Cefotaxime 
32 (4.9) 
Ciprofloxacin 
27 (4.1) 
Co-amoxiclav 
27 (4.1) 
26-65years Ceftriaxone  
471 (34.2) 
Metronidazole 
241 (17.5) 
Ciprofloxacin 
111 (8.1) 
Moxifloxacin  
61 (4.4)  
Co-amoxiclav 
57 (4.1) 
>65years Ceftriaxone 
83 (37.6) 
Moxifloxacin 
20 (9.0) 
Metronidazole 
19 (8.6) 
Meropenam 
13 (5.9) 
Piperacillin & 
enzyme inhibitor 
10 (4.5) 
 
INDICATIONS      
Community acquired 
infection 
Ceftriaxone  
237 (27.9) 
Metronidazole 
95 (11.2) 
Ampicillin 
43 (5.1) 
Vancomycin  
40 (4.7) 
Moxifloxacin 
40 (4.7) 
Hospital acquired 
infection 
Ceftriaxone 
25 (16.9) 
Piperacillin & 
enzyme inhibitor 
16 (10.8) 
Metronidazole 
13 (8.8) 
Meropenam 
9 (6.1) 
Amikacin 
9 (6.1) 
Medical Prophylaxis Ceftriaxone 
278 (52.2) 
Metronidazole  
43 (8.1) 
Ciprofloxacin  
31 (5.8) 
Moxifloxacin 
24 (4.5) 
Piperacillin & 
enzyme inhibitor 
18 (3.4) 
Surgical Prophylaxis Ceftriaxone 
310 (34.7) 
Metronidazole 
238 (26.7) 
Ciprofloxacin 
63 (7.1) 
Cefoperazone 
54 (6.0) 
Cefotaxime 
42 (4.7) 
Unknown/others Ceftriaxone 
18 (30.5) 
Metronidazole 
8 (13.6) 
Ciprofloxacin  
5 (8.5) 
Levofloxacin 
3 (5.1) 
Co-amoxiclav 
3 (5.1) 
 
 
 
